February 28, 2017 / 12:20 PM / 9 months ago

BRIEF-Tonix Pharmaceuticals to present breakthrough therapy designated-PTSD program

Feb 28 (Reuters) - Tonix Pharmaceuticals Holding Corp

* Tonix Pharmaceuticals Holding - to commence in this quarter 12-week Phase 3 clinical study, “honor” study, evaluating TNX-102 sl, 5.6 mg, in military-related ptsd

* Tonix Pharmaceuticals Holding - interim analysis of honor study is expected in first half of 2018, topline results are expected in second half of 2018 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below